Compare ADNT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADNT | OCS |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | Ireland | Switzerland |
| Employees | N/A | 60 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2016 | N/A |
| Metric | ADNT | OCS |
|---|---|---|
| Price | $23.22 | $11.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $25.41 | ★ $42.00 |
| AVG Volume (30 Days) | 906.0K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $17,439,000,000.00 | N/A |
| Revenue This Year | $2.71 | $466.06 |
| Revenue Next Year | $2.36 | $479.73 |
| P/E Ratio | $378.00 | ★ N/A |
| Revenue Growth | ★ 7.56 | N/A |
| 52 Week Low | $17.70 | $10.52 |
| 52 Week High | $27.32 | $34.48 |
| Indicator | ADNT | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 58.09 | 23.69 |
| Support Level | $18.79 | $10.52 |
| Resistance Level | $23.84 | $21.82 |
| Average True Range (ATR) | 1.01 | 1.75 |
| MACD | 0.01 | -0.71 |
| Stochastic Oscillator | 59.24 | 4.31 |
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.